AstraZeneca Faces Patent Challenge For Best-Selling Drug

Law360, New York (September 28, 2005, 12:00 AM EDT) -- Israeli drug maker Teva Pharmaceutical Industries Ltd. is seeking to produce a generic version of the schizophrenia drug Seroquel, which garnered drug originator AstraZeneca $2 billion in worldwide sales last year.

Teva has filed an Abbreviated New Drug Application with the Food and Drug Administration (ANDA) with the U.S. Food and Drug Administration to make a 25 mg version of Seroquel.

Seroquel is the Anglo-Swedish company’s best selling drug, with sales accounting for nearly 10% of AstraZeneca’s revenues. In the U.S. alone, the drug generated $1.5...
To view the full article, register now.